CrunchBase : Data Infrastructure Startup Cribl Locks Up $319M At $3.5B Valuation

Data Infrastructure Startup Cribl Locks Up $319M At $3.5B Valuation

San Francisco-based Cribl raised a $319 million Series E led by new investor GV and valuing the data infrastructure company at $3.5 billion.

The new round is actually a mix of $200 million in capital and a $119 million secondary offering, per Bloomberg. The raise represents a significant up-round for the company, which last raised a $150 million Series D led by Tiger Global Management at a valuation of nearly $2.6 billion in 2022.

The new round also included participation from GIC, CapitalG, IVP and CRV.

Managing data
Cribl’s platform gives users observability into their data, allowing them to understand the health of the data and organize it for IT and security teams. Just last year, Cribl announced it had passed the $100 million mark in annual recurring revenue. The company has more than 700 employees worldwide.

While the explosion of data has given companies the potential for deep understanding of their business, the process of actually collecting, verifying and organizing that data has proven to be difficult and time-consuming. It’s that problem that platforms such as Cribl’s tries to rectify.

“Every company must modernize its data stack as legacy systems already can’t handle today’s rapid data growth, and the arrival of AI further accelerates the need for a modern data platform,” said Michael McBride, GV general partner and part of Cribl’s board, in a release. “Cribl’s rapid growth has come from the consistent and powerful results experienced by its customers.

Founded in 2018, Cribl says it has raised more than $600 million.

9to5 : One big reason you may want to hold out for the iPhone 17

One big reason you may want to hold out for the iPhone 17

One big reason you may want to hold out for the iPhone 17 | iPhone 17 render
If you don’t upgrade every year, and were planning on buying an iPhone 16, a leaker with a solid track record has just given a potentially good reason to hold out for the iPhone 17 instead.

According to their Weibo post, the iPhone 17 will get 12GB of RAM, over the 8GB of the iPhone 16 line-up, and suggested this will offer a significant benefit when using Apple Intelligence features …

iPhone 17 to get 12GB RAM
Weibo user Mobile phone chip expert (MPCE) reports:

If you want to change to an AI iPhone, maybe the 2025 iPhone 17 is a good choice. This year’s iPhone 16 internal memory is only 8GB, mainly cloud-side AI. Next year’s iPhone 17 internal memory is 12GB, and there are more on-device AI applications.

Apple is slowly ramping up RAM. All iPhone 14 models had 6GB RAM, Pro or not. For the iPhone 15, the base and Plus models were powered by the A16 Bionic chip from the previous year’s Pro models, and remained on 6GB RAM. The two Pro models not only got the A17 Pro chip, but also saw their RAM boosted to 8GB.

It’s notable that only the two Pro models are capable of running Apple Intelligence, which is likely due to a mix of both processor power and RAM. That idea is backed by the fact that all four iPhone 16 models are expected to get 8GB RAM.

On-device AI to be ramped-up next year
MPCE suggests that the shift to 12GB RAM is because Apple plans to power more Apple Intelligence features on-device, with fewer functions dependent on cloud processing.

If the iPhone 17 can more AI functions locally, while other iPhones have to use Apple’s Private Cloud Compute (PCC) servers, that could make next year’s models significantly faster when it comes to using some Apple Intelligence features, as well as being more secure.

9to5Mac’s Take
Mobile phone chip expert has a limited but good track record when it comes to Apple’s chip plans. They were first to reveal that the A16 processor would be exclusive to the two iPhone 14 Pro models, and more recently that Apple was developing its own 3nm chips for its AI servers. That means the suggestion that next year’s iPhones will get 12GB RAM has to be taken seriously.

Whether that has significant implications for Apple Intelligence is more speculative. The leaker clearly has visibility into Apple’s supply-chain, but that wouldn’t tell them why any particular changes are being made.

All the same, it does seem at least a solid theory, and is consistent with both Apple’s preference for on-device processing wherever possible, and the strong clue that RAM is a factor when running Apple Intelligence.

Of course, ultimately it depends on how long you’re willing to wait to gain access to Apple Intelligence. If you don’t currently own an iPhone 15 Pro or Pro Max, then you’ll need to upgrade this year unless you’re willing to wait another 12 months. But given that we’re not expecting the new Siri to launch until sometime next year anyway, waiting until next September might not be too painful.

TechCrunch : Apple introduces AI-powered object removal in photos with the lates

Apple introduces AI-powered object removal in photos with the latest iOS update

Apple released the new developer betas for iOS 18.1, iPadOS 18.1, and macOS 15.1 Sequoia. With this update, the company is launching new Apple Intelligence features, including the ability to remove objects from photos.

The feature, called Clean Up, lets users identify and remove an object from the photo without affecting the picture. The system uses AI to generate background when you remove an object from an image. Apple said that the system understands even shadow or reflection of an object and handles it while filling in the background.

Users can select an object using the smart detection feature to remove it with just one tap. People can also circle or brush over any unwanted objects to delete them from the image.

Apple’s rival Google made a similar feature called Magic Eraser available to all Google Photos users for free earlier this year.

In July, Apple rolled out the first set of Apple Intelligence features with iOS 18.1 dev beta. These features included writing tools, notification summaries for SMS and Mail, natural language search and memory creation in Photos, transcription for calls and voice recordings in notes, and summaries and smart replies feature in Mail. Apple Intelligence is only available to users in English with their region set to the U.S.

WSJ : French Authorities Charge Telegram Founder Pavel Durov

French Authorities Charge Telegram Founder Pavel Durov
The move opens a deeper probe into whether the tech entrepreneur failed to counter the spread of illegal content on the app

PARIS—French judicial authorities brought preliminary charges against Telegram founder Pavel Durov for a host of crimes, including complicity in distributing child pornography, illegal drugs and hacking software on the messaging app—a stunning blow for an entrepreneur who became a hero for internet libertarians over the past decade.

The authorities also charged Durov with refusing to cooperate with investigations into illegal activity on Telegram. Paris prosecutor Laure Beccuau cited “an almost complete absence of response from Telegram to judicial demands.”

The charges are the most significant test yet facing Telegram and Durov, and they represent a major escalation by the French government in holding tech executives accountable for the content that appears on their platforms. The arrest of Durov, who for years has resisted government attempts to regulate Telegram, has thrust the entrepreneur to the center of debate over how far authorities should go, with executives such as Elon Musk coming to his defense.

Wednesday’s decision means French judges thought there was enough evidence against Durov to deepen their investigation into whether he violated French laws that require online platforms to limit harmful content and cooperate with authorities. If convicted of complicity in illegal online transactions, Durov faces up to 10 years in prison and a fine of €500,000, about $550,000.

The judges placed Durov under court monitoring, forbade him from leaving France and required him to post bail of €5 million. He will have to appear at a police station twice a week. After an investigation that is likely to take months or even years, judges ultimately could decide to drop the charges.

Durov, 39 years old, was arrested Saturday night when his private jet landed at Le Bourget airport north of Paris. One of his lawyers, David-Olivier Kaminski, said it was “totally absurd to think that the head of a social network could be involved in criminal acts that do not concern him, either directly or indirectly.”

Beccuau said Telegram had popped up repeatedly in investigations into child pornography, drug trafficking and inciting racial hatred online since the app’s launch in 2013. Other prosecutors around France and in other European countries noted the same trend when the Paris prosecutor consulted them, she said. That prompted French investigators to examine whether Telegram executives were criminally liable for the illegal activity taking place on the platform.

The requirements imposed by the court are likely to put an end to the jet-setting lifestyle of Durov, who has spent the past decade bouncing between Russia, Europe and the Middle East, accumulating nationalities along the way. Born in Soviet Russia, he became a citizen of France and the United Arab Emirates in 2021. He also has citizenship for St. Kitts and Nevis, an island in the Caribbean that offers it for those who can pay.

His arrest and charges have unnerved people across the social-media industry, said Sarah Oh Lam, senior fellow at the Technology Policy Institute, a Washington think tank that is largely funded by the tech industry.

“Folks are very concerned,” said Oh Lam. “What does it mean that the French government can arrest someone upon landing in France? At least from our vantage point they need to reveal more of the facts.”

What is clear is that Telegram isn’t like U.S. Big Tech companies, which employ armies of lawyers and government relations executives to respond to demands from law enforcement. For years, the company ignored subpoenas and court orders sent by authorities, which piled up in a rarely checked company email address, according to a person close to Durov.

An office rented by Telegram in an office building complex in Dubai was closed on Wednesday. A receptionist in Business Central Towers said Telegram was registered as a tenant for several years, but she had never seen anyone from the company work out of the more than 3,000-square-foot office in her time there. She also said she couldn’t find any contact details for the company or one of its representatives on the building security system, which she said was usually updated with such information for most other tenants there.

Durov has a murky history with governments around the world, which have sought to both target him and win him over. In 2018, French President Emmanuel Macron invited Durov to move Telegram to Paris during a lunch meeting, The Wall Street Journal has reported.

A year earlier, French spies had joined their counterparts from the U.AE. to hack into Durov’s phone. French security officials were concerned about Islamic State’s use of Telegram to recruit operatives and plan attacks.

Russia in 2018 attempted to block Telegram, saying the platform didn’t cooperate in terrorism investigations. But Telegram continued to thrive there even as authorities prevented thousands of IP addresses a day from accessing the app, the company said. Moscow in 2020 abandoned the blockade, saying Telegram had promised to fight terrorist content on its platform. A Telegram spokesman denied there was any deal with Russia and said the company had a “zero compromise” policy for bans in authoritarian countries.

Durov imposed few, if any, restrictions on content shared on Telegram, despite mounting concern, particularly in Europe, that big online platforms were enabling illegal activity, spreading misinformation and fueling racism and antisemitism. Telegram says it now complies with the European Union’s Digital Services Act, which requires online companies to cooperate with authorities in countering the spread of illegal content on their platforms.

Durov founded Telegram in 2013 as Russian authorities began demanding information about users of an earlier company he co-founded, VKontakte, a social-media platform that earned him a reputation as the Mark Zuckerberg of Russia. He left Russia the next year, saying the Kremlin was pressuring him to turn over user data of Ukrainians protesting the then pro-Russian government in Kyiv.

Durov rebuffed agents from the Federal Bureau of Investigation who would typically be waiting for him when he landed in the U.S., he said in an interview earlier this year with Tucker Carlson.

“My understanding is they wanted to establish a relationship to, in a way, control Telegram better,” Durov said.

WSJ : Violent Drug Gangs Bring Mayhem to Western Europe

Violent Drug Gangs Bring Mayhem to Western Europe
Dutch cocaine kingpin sentenced to life in prison after deadly crime spree; ‘violence is destabilizing society’

AMSTERDAM—Organized crime used to be considered a remote threat in much of Western Europe, but ruthless violence by criminal gangs is now rattling the peace in some of the world’s safest societies.

Sweden now has Europe’s highest gun-homicide rate, and the military is helping police fight street gangs. In Denmark, residents of the commune Christiania shut their famed open-air cannabis market after violent gangs took over. In Belgium, armed security forces have started guarding customs trucks carrying seized cocaine to prevent criminals from stealing it back.

One of the most alarming exhibits of what the 21st century drug trade has wrought upon long-peaceful European societies came earlier this year in the Netherlands, long known for its tolerant attitude toward recreational drugs.

Dutch drug kingpin Ridouan Taghi was considered so dangerous that he was tried in a warehouse-turned-bunker in Amsterdam, guarded by hundreds of masked special forces and drones circling overhead to prevent a prison break. When the judges pronounced him guilty of involvement in five murders and two attempted killings, their faces were hidden and their names weren’t revealed.

“He has managed to strike fear in the minds of people,” said Dutch lawmaker Ulysse Ellian about Taghi, who was sentenced to life in prison.

During the six-year legal proceeding that led to Taghi’s conviction, three people linked to the state’s star witness were shot dead in the streets of Amsterdam: his brother, his lawyer and a well-known crime journalist who had joined the witness’s legal team.

“We have seen murders before. What’s new about Taghi is that he also targets individuals who are not part of the criminal underworld: the brother of the star witness, a lawyer, a journalist,” said Robby Roks, associate professor of criminology at the Erasmus School of Law in Rotterdam. The case, he said, “raises all these questions about what these criminals with seemingly unlimited resources can do from prison.”

Late last month, Taghi’s 23-year-old son, Faissal, was extradited from the United Arab Emirates at the request of Dutch authorities on suspicions of participating in a criminal organization involved in international drug trafficking, money laundering and preparing violent crimes. He is now locked up in the same maximum-security prison as his father.

Ellian, a newly elected member of parliament, is pressing for dangerous prisoners to be cut off from other inmates and people outside. Without fast action “we’re taking huge risks,” he said. “The more of these top guys you arrest, the more urgent it becomes.”

A recent report by Europol, the law enforcement arm of the European Union, and EMCDDA, the EU’s drug agency, said several European countries are suffering “unprecedented levels of drug market-related violence, including killings, torture, kidnappings and intimidation.” The report identified 821 serious criminal networks active in the EU, with more than 25,000 members.

The EU now considers organized crime a threat to European societies on par with terrorism.

“Violence is destabilizing society and the social contract we have known,” said Europol deputy spokesperson Claire Georges. “It used to be more at transit points, such as airports, and among specific groups. Now, violence is increasingly spilling onto the streets with the risk of civilians being hurt.”

Europol attributes the violence to a globalization of the drug trade, a surge in coca cultivation in Colombia and a fragmentation of the supply chain. Gangs have established a firmer foothold in large European ports, including Rotterdam in the Netherlands and Antwerp-Bruges in Belgium.

In 2019, cocaine seizures in Europe exceeded those in North America for the first time, according to the United Nations Office on Drugs and Crime. In 2021, the most recent year for which data is available, EU authorities seized more than 300 tons of cocaine, a record.

The kingpin
Taghi, who is 46, was born in Morocco and moved to the Netherlands, near Utrecht, as a young child. As a teenager, he joined a gang operating in local shopping malls, according to Dutch news reports and a documentary about his life. In the early 2000s, Taghi split his time between Dubai and Morocco, smuggling hashish into the Netherlands, according to the news reports.

Rising cocaine consumption in Europe prompted South American cartels to begin pivoting to that market around 2008, and Taghi entered the global cocaine trade. At one point, his gang imported about one-third of all cocaine going into the Netherlands, according to police documents cited in Dutch news reports.

The Dutch economy has long depended on international commerce, and the Port of Rotterdam is Europe’s largest. “Everything that makes the Netherlands attractive for the legal economy also makes it attractive for the illegal economy,” said Pieter Tops, professor emeritus at Leiden University and author of several books on the societal effects of organized crime.

Since the 1970s, lax and contradictory drug laws have nurtured a criminal underworld. Recreational use of cannabis is legal, but production isn’t. That opened a door for organized crime groups to supply Dutch “coffee shops.” Gangs expanded to trafficking cocaine and producing synthetics such as ecstasy, said Stijn Hoorens, director of the Rand think tank’s Netherlands office and drug-policy expert.

Dutch prosecutors say the killings Taghi was convicted of began in 2015 when he ordered the murder of a spy-shop owner who had given police his transaction records, including about surveillance equipment sold to his gang. A crime blogger who had published Taghi’s name was shot dead outside a sex club north of Amsterdam, though a court later found insufficient evidence that Taghi was behind the murder.

In 2016, Taghi relocated to Dubai using a Dutch passport with a fake name, according to Emirati police. He stayed out of reach of Dutch authorities while conducting business in Europe.

Then he was betrayed. In 2017, a murder in Utrecht that Dutch prosecutors said Taghi ordered went wrong, when the hit men killed the wrong person. The middleman who arranged the killing turned himself in to Dutch police and offered to testify against Taghi.

Dutch authorities charged Taghi in absentia with collusion in six murders and more than a dozen planned killings and hit operations, and began pretrial sessions that would extend over several years.

One state witness, the middleman referred to as Nabil B., paid a price for betraying Taghi. In 2018, his brother was shot dead outside his office in Amsterdam. The following year, Nabil B.’s lawyer, Derk Wiersum, was killed by a hoodie-clad man who fled on foot.

There were other shocking stories of violent crime. In 2016, the decapitated head of a gang member was found looking in through the window of an Amsterdam cafe. In 2020, police discovered shipping containers converted into what appeared to be soundproof torture chambers equipped with pliers, blowtorches and a dentist’s chair with shackles.

In 2019, Dubai police arrested Taghi following a manhunt and deported him to the Netherlands. On his encrypted BlackBerry, police found pictures of a woman being tortured.

Taghi was confined to a Dutch maximum-security prison during the legal proceedings. In 2021, the country’s best-known crime reporter, Peter de Vries, who had joined the prosecution witness’s legal team, was shot dead leaving a television studio in Amsterdam.

Taghi’s first lawyer was arrested after a police investigation found that the two used meetings intended to prepare for trial to discuss prison break plans. One scenario involved mercenaries shooting Taghi’s way out of prison, “the Navy Seals way,” according to an intercepted note. Taghi’s second lawyer was arrested on allegations that she had passed messages to people outside.

During the trial, Dutch authorities worried that Taghi’s men might try to break him out of prison by kidnapping prison staff and forcing an exchange. Dutch Prime Minister Mark Rutte stopped riding his bicycle to work, and Dutch Crown Princess Amalia canceled her first year of university—both apparently due to kidnapping threats from Taghi. The threats were disclosed in a court case against his cousin, who had been arrested while acting as his lawyer.

A survey last year showed that half of all Dutch judges and prosecutors felt less safe in their work due to threats or intimidation, and that nearly one-third of them had changed their work routines, including by replacing their name on case files with a code.

The lawmaker
Ellian, a 35-year-old Afghan-born member of parliament, said he first came across Taghi in 2018. Then a member of a municipal council, Ellian publicly accused Iran of ordering the 2015 murder of an Iranian dissident in his town. The man convicted of arranging the murder, Naoufal Fassih, was a hit man for Taghi, according to the indictment. Through a lawyer Fassih filed a disciplinary complaint against Ellian.

The implicit message, Ellian said, was: “We’re watching you. Stop talking.”

Ellian launched a political career by pledging to confront Taghi and other dangerous prisoners who he has said threaten the country’s democracy.

In 2021, as a newly elected center-right member of parliament, he traveled to the onetime Mafia hotbed of Palermo, in Sicily, to learn about the Article 41-bis regime, which since the early 90s has allowed the Italian government to impose the near-complete isolation of a prisoner.

He toured the Colorado prison housing Mexican drug lord Joaquín “El Chapo” Guzmán, who recently complained to authorities that he hadn’t been allowed to speak to his wife and daughters for seven months.

Ellian wants the Netherlands to implement a similar system—something as harsh as possible under European human-rights law.

The Dutch Parliament is set to debate a bill he proposed to restrict high-risk detainees to two phone calls and one visit a month. In June, he succeeded in allocating about $33 million to expand the country’s maximum-security prison by another 12 cells.

Fearing retaliation from Taghi’s gang, Ellian receives police protection from the unit that protects the Dutch royal family.

“It’s not personal,” he said. “Although for Taghi, it might be.” He spoke during a drive home from parliament with the siren on his government car blasting as the bodyguard-driver blew through red lights. Next to the driver sat a second armed guard in body armor.

Last year, Ellian accompanied prison staffers in the city of Roermond on a night raid to confiscate phones. His face covered by a balaclava, he followed prison guards as they threw open cell doors and used dogs to find hidden phones.

His efforts have drawn the attention of inmates. Walking through a Dutch prison recently, a prisoner barked out his name. On another visit, Ellian said, an inmate called out, “Why are you always trying to make things harder for us?”

In public court sessions, Taghi has criticized Ellian for abusing his political power to restrict the rights of prisoners.

“We Europeans take freedom and living in a secure country for granted,” Ellian said. “But you have to stand up for it. A free country can change into something ugly very fast.”

FT : From Covid to cancer: BioNTech and Moderna’s bet on personal vaccines

From Covid to cancer: BioNTech and Moderna’s bet on personal vaccines
Pandemic winners face hurdles as they seek to bring their groundbreaking technology to oncology

Steve Haycock had most of his colon removed last year but doctors have told the 43-year-old that his bowel cancer is highly likely to come back — unless a personalised vaccine trial pays off.

The product is made by German Covid-19 jab maker BioNTech, which has identified proteins specific to mutations in his cancer cells and designed a vaccine that will prime his immune system to attack new tumours containing them.

“It’s given me a lot of confidence to be on this trial,” he said. “I’m only in this position because things are going badly for me but I do feel privileged.”

BioNTech and US coronavirus jab rival Moderna, both of whose shares have slid about 80 per cent since their 2021 pandemic peaks, are betting on cancer vaccines to revive their fortunes. Using the mRNA technology behind their Covid products, they hope to drastically improve outcomes and lead a new field of cancer care.

But it is early days for personalised vaccine technology and many hurdles remain. Making a personalised vaccine for each patient will be costly and come with supply chain challenges, while pharma groups are constantly advancing other drug types in the ever competitive cancer field.

While “it’s very attractive and very exciting”, said Miranda Payne, a melanoma specialist leading a Moderna trial at Oxford’s Churchill Hospital, “it’s a little bit hard to see how you’ll scale it up for everybody who might need it”.


Several companies have tried to develop cancer vaccine-style products in recent years but the products have struggled to induce an effective response to tumours, especially in late-stage cancer when the immune system is already weak.

“Vaccines have historically been an abysmal investment,” said Marek Poszepczynski, an oncology expert at life sciences investor the International Biotechnology Trust. “Cancers are very, very good at escaping the immune system.”

BioNTech and Moderna are hoping to succeed where others have failed as they seek to develop broad portfolios of cancer treatments. Bolstered by Covid-19 revenues, both spent record sums on research and development last year.

BioNTech’s product, available to Haycock through an NHS trial, is years from commercialisation. Moderna’s jab for melanoma, a type of skin cancer that can spread to other areas of the body, was developed with Merck and is in more advanced trials.

As mRNA taught the immune system to recognise and fight Covid-19, it can instruct immune cells to recognise proteins known as neoantigens that are particular to mutations in an individual’s cancer.

Every Moderna jab is tailor-made, with each patient’s tumour genomically sequenced to select the best-suited 34 neoantigens. The vaccine then directs the immune system to recognise these neoantigens and attack future cancer cells that contain them.

The BioNTech product used to treat Haycock is being co-developed with Roche subsidiary Genentech and works similarly, with up to 20 neoantigens selected.

Although it rose to global prominence through Covid, BioNTech’s main focus since it was founded in 2008 has been cancer. “Personalisation of our mRNA vaccines is our most important innovation,” Uğur Şahin, chief executive, told the Financial Times.


Moderna chief executive Stéphane Bancel recalled how he told staff late in the pandemic that “10 years from now, people would have forgotten what we did for the world during the pandemic because we’ll be known as one of the most impactful cancer product companies”.

Positive data in June from a mid-stage trial of the company’s skin cancer jab showed that a personalised vaccine could be closer than ever. “Some investors are sceptical but this is a science business,” Bancel added.

Among a group of 157 late-stage melanoma patients treated with Merck’s blockbuster cancer immunotherapy Keytruda, the risk of death or disease recurrence fell 49 per cent among those who also received Moderna’s vaccine. Moderna is now pushing ahead with late-stage trials.

Combining products with treatments such as Keytruda could prove key to realising vaccines’ potential.

Merck’s drug is the most successful of a wave of immunotherapies known as checkpoint inhibitors. First approved by the US Food and Drug Administration in 2014 for advanced melanoma patients, Keytruda is now used against 17 cancer types, including breast, lung, blood and skin cancers. It was the world’s highest-selling drug last year with $25bn in sales.

Checkpoint inhibitors “remove the brakes” on immune system cells that stop them from attacking tumours, said Lawrence Young, an oncology professor at the University of Warwick, while vaccines then direct the immune cells to target the cancer.

While only 20-40 per cent of patients respond to the drugs, experts say the dual action of the vaccines could increase this number.

“Scientifically, it makes a lot of sense to combine them,” said Peter Kiener, an investor with ICG Life Sciences who is an oncology expert. “If you can add on a vaccine that’s tolerable, you could change that response rate from 20-30 to 50-60 per cent of patients. Then you really can have a tremendous impact on the disease.”

BioNTech is also trialling a personalised melanoma vaccine to be delivered alongside Keytruda but is developing another melanoma jab to be used with a checkpoint inhibitor developed by Regeneron. The company said last month that tumours had shrunk more in patients receiving the vaccine than in those on standard treatment, although it has not disclosed detailed results.

The personalised approach does have drawbacks. “It’s very expensive if you have to sample the tumour, sequence it and make a bespoke vaccine,” said Young. “While the individualised approach is exciting and will be proof of principle, I suspect there will be a more generalised approach.”

BioNTech is trying both strategies: its melanoma product with Regeneron is an “off-the-shelf” jab that uses just four melanoma antigens, at least one of which is present in 90 per cent of melanomas. This could be cheaper to produce but less targeted than the Moderna product.

It is one of eight ongoing trials for mRNA cancer vaccines that BioNTech is conducting, including personalised vaccines for lung, pancreatic and colorectal cancer.

But Moderna is likely to be first to market. Having shown the potential of its jab in melanoma, the company is launching phase-three trials testing the jab on the most common type of lung cancer and another form of skin cancer, as well as earlier-stage trials in kidney and bladder cancer, among others.

It also plans to study its cancer vaccine as a standalone treatment on patients with early-stage cancer, without administering Keytruda as a dual therapy.

“The ambition we have with Merck is to take [the cancer vaccine] to all the places and make it just as big as the checkpoint inhibitors have become,” said Stephen Hoge, Moderna’s president who runs its research and development efforts.

In Oxford, Payne has been helping patients who have had melanoma surgery participate in the Moderna phase-three trial.

“There’s been huge interest in it”, she said, adding that Moderna reached its recruitment goal for participants in June, well ahead of an original mid-2025 target.

But Payne’s experience also points to other challenges for the vaccine makers. She said one in four patients suggested by her had been turned away because of issues with the tumour samples and identifying enough neoantigens to make the vaccines.

To bolster its supply chain, Moderna has invested $322mn in a vaccine manufacturing facility in its home state of Massachusetts. BioNTech is also investing in new facilities near its headquarters in Mainz, Germany, that it hopes to open by the end of the year.

But Kyle Holen, Moderna’s oncology head, admitted that the process of sequencing the tumours could still be smoother. Moderna cannot currently use sequencing data from a patient’s biopsy to diagnose their cancer, meaning a second set of tests has to be carried out.

Şahin said he expected the drugs to be more expensive than existing immunotherapies and that the price tags would have to be justified by preventing future strains on healthcare systems.

“It can only be expensive if it really addresses a high medical need and if it reduces downstream costs associated, for example, by preventing metastatic cancer,” he said.

But several experts added that there were alternatives that could also prevent cancers returning, potentially at a lower cost.

A 2023 study found that giving advanced melanoma patients Keytruda both before and after surgery, instead of only after, could also delay cancers from recurring. Three-quarters of patients who received it before and after had no cancer within two years, against half who received the drug only after surgery.

Merck also recognises there are limitations to the vaccines. “The Achilles heel of this particular therapy is that it requires that the immune system remains intact so they can create an immune response,” said Eliav Barr, Merck’s chief medical officer, meaning younger patients would be most likely to benefit from the drug.

And despite the impressive melanoma data, experts remain doubtful about how helpful vaccines will be against other cancers or as a standalone treatment.

Melanoma is among the cancers with the highest frequency of genetic mutations, lending itself to be targeted by immunotherapy, according to Elizabeth Jaffee, a professor of oncology at Johns Hopkins University. Vaccines may not fare as well against less immune-responsive cancers, she said.

Meanwhile, rival pharma players are also advancing alternative treatments such as CAR-T therapies, another highly costly, personalised product where patients’ immune cells, or T cells, are extracted and genetically modified to better kill cancer cells before being reinjected.

“The cancer vaccines are going to have to show they can compete against [a] raising bar,” said Susan Galbraith, head of research and development at AstraZeneca, which is backing CAR-T and cell therapies.


Still, both BioNTech and Moderna have made significant progress in recent years. Once Moderna’s phase 3 trial is fully enrolled, the company will apply to the US FDA for an accelerated approval, Bancel said, which could come as early as next year.

BioNTech’s products will take longer to advance but Şahin said he expected to be able to launch new cancer treatments by 2026, with a personalised vaccine coming before 2030. The products, he believes, will be similarly impactful as checkpoint inhibitors such as Keytruda.

“We shouldn’t forget this is not only a new product but a new concept, a new technology,” he said. “Vaccines are one of the [treatments] with the greatest scepticism but I see more and more people being enthusiastic about them.”

One of the enthusiasts is Haycock, who is eight rounds into almost 20 appointments at which he receives the vaccine.

“I’ve gone from leading my life thinking it’s only a matter of time before my cancer is going to come back to thinking, if this works, I won’t necessarily have to worry too much,” he said.

>>> US After Hours Summary: AFRM +15%, CRM +2.8%, CRWD +2% among gainers followi

After Hours Summary: AFRM +15%, CRM +2.8%, CRWD +2% among gainers following earnings; PSTG -14.3% and NVDA -5.9% slipping after reporting quarterly results; BIG -27.3% down big after considering bankruptcy, according to Bloomberg

After Hours Gainers:

Companies trading higher in after hours in reaction to earnings/guidance: AFRM +15%, NTNX +14%, FIVE +7.4%, IREN +5%, VEEV +4.3%, VSCO +3%, CRM +2.8% (CFO transition), COO +2.3%, CRWD +2%

Companies trading higher in after hours in reaction to news: NOAH +0.6% (authorizes $50 mln repurchase plan), X +0.6% (investments at Mon Valley works and Gary Works), LMT +0.2% (awarded multiple U.S. Navy contracts)

After Hours Losers:

Companies trading lower in after hours in reaction to earnings/guidance: PSTG -14.3%, APLD -13.6%, OKTA -7.8%, NVDA -5.9% (also approves additional $50 bln for repurchases) HPQ -3.5%, NTAP -3% (also announces new capabilities that support VMware)

Companies trading lower in after hours in reaction to news: BIG -27.3% (considering bankruptcy filing, according to Bloomberg), SMCI -5.2% (previews new architecture), RPTX -4.6% (reducing workforce by 25%), DAWN -3.4% (stock offering), DCTH -2.1% (results from study on liver-directed therapy), SYY -1.9% (files mixed shelf), TSLA -1.2% (requested Canada lower China-made EV tariff, according to Reuters), MEI -0.8% (appoints new CFO), RDDT -0.7% (investigating outage, according to Reuters), MSFT -0.5% (OpenAI valued at over $100 bln, according to WSJ), CMG -0.3% (appoints new CFO), GOOG -0.3% (releases new Gemini features), GS -0.3% (Fed reduces stress capital buffer requirements), FMC -0.1% (district court grants temporary restraining order against Sharda USA), BJRI -0.1% (CEO stepping down; names interim CEO)

Le Figaro : Le PDG de Telegram Pavel Dourov mis en examen et remis en liberté so

Le PDG de Telegram Pavel Dourov mis en examen et remis en liberté sous contrôle judiciaire

La garde à vue de Pavel Dourov a été levée mercredi, plus de trois jours après son interpellation à l’aéroport du Bourget.

La garde à vue de Pavel Dourov, fondateur et patron de la messagerie cryptée Telegram, a été levée mercredi en début d’après-midi, mais les soupçons qui le visent demeuraient, en fin de journée, assez flous. Au terme d’un interrogatoire qui s’est étendu sur plus de trois jours, l’entrepreneur de 39 ans a été présenté à un juge d’instruction. Il a ensuite été mis en examen dans la soirée et remis en liberté sous contrôle judiciaire. Cette comparution s’est déroulée dans le cadre d’une information judiciaire ouverte le 8 juillet dernier, à l’issue d’une brève enquête préliminaire diligentée par la section de lutte contre la cybercriminalité du parquet de Paris. La procédure vise douze infractions distinctes, mais on ignore encore quels faits précis sont reprochés à ce ressortissant russe, qui possède également les nationalités française et émirienne.

Interpellé samedi soir par la police aux frontières à l’aéroport du Bourget (Seine-Saint-Denis), où son jet privé venait de se poser en provenance d’Azerbaïdjan, Pavel Dourov a été interrogé par les gendarmes du Centre de lutte contre les criminalités numériques ainsi que par les douaniers de l’Office national antifraude. Les questions semblent s’être notamment focalisées sur les mécanismes de régulation de la plateforme Telegram, dont le patron se targue de garantir la confidentialité, ainsi que sur son utilisation pour partager des contenus criminels ou délictueux. 

Images pédopornographiques et de produits stupéfiants

L’information judiciaire, ouverte à l’encontre de plusieurs suspects qui ne sont pas explicitement nommés, porte notamment sur la diffusion d’images pédopornographiques et de produits stupéfiants. Elle vise aussi des faits de complicité d’escroquerie en bande organisée, d’association de malfaiteurs et de blanchiment. Les juges soupçonnent notamment les dirigeants de Telegram d’avoir refusé « de communiquer, sur demandes des autorités habilitées, les informations ou documents nécessaires pour la réalisation et l’exploitation des interceptions autorisées par la loi ».


Pavel Dourov a été arrêté en application d’un mandat émis en mars dernier, à l’initiative du parquet de Paris, alors que la plateforme avait laissé « sans réponse » plusieurs requêtes adressées par la justice française. Selon le site Politico, ce document viserait également Nikolaï Dourov, frère de Pavel et cofondateur de la messagerie. « À ce stade, la seule personne mise en cause dans ce dossier est Pavel Durov », précise toutefois une source judiciaire. Le mandat aurait été délivré dans le cadre d’une enquête portant sur la diffusion de matériel pédopornographique.

Par ailleurs, une seconde enquête serait ouverte visant Pavel Dourov pour des « violences graves » sur un de ses enfants à Paris, confiée à l'Office des mineurs (Ofmin). Les faits auraient été commis sur un fils du milliardaire né en 2017, alors qu'il était scolarisé à Paris. Le jeune garçon vit désormais en Suisse avec sa mère, qui a déposé plainte dans ce pays en 2023, accusant son ex-compagnon de violences sur un de ses enfants, a poursuivi la source proche du dossier.

L’arrestation de Pavel Dourov, qui réside à Dubaï depuis plusieurs années, a suscité de vives réactions à travers le monde. « Telegram se conforme aux lois européennes, y compris le règlement sur les services numériques, son action de modération est dans la norme du secteur », s’est défendu dimanche soir Telegram sur son propre canal, jugeant « absurde de dire qu’une plateforme ou son patron sont responsables des abus » relevés sur la plateforme.